Compare Stocks: MNOV, CRBP, CERC, and HROW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERC Cerecor	$14.41 -9.5%	$2.60	$1.98 ▼ $4.50	$1.38B	1.44	1.27 million shs	1.58 million shs
CRBP Corbus Pharmaceuticals	$10.38	$9.17	$7.12 ▼ $20.56	$193.81M	2.59	365,355 shs	604,014 shs
HROW Harrow	$40.95	$41.46	$28.54 ▼ $54.85	$1.54B	0.28	554,617 shs	466,460 shs
MNOV MediciNova	$1.39	$1.35	$1.17 ▼ $1.96	$68.42M	0.63	33,471 shs	25,994 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERC Cerecor	0.00%	0.00%	0.00%	0.00%	+45.85%
CRBP Corbus Pharmaceuticals	0.00%	+2.87%	+13.20%	-8.55%	+6.03%
HROW Harrow	0.00%	+2.30%	+6.50%	+24.09%	+4.68%
MNOV MediciNova	0.00%	+6.11%	+5.30%	-0.71%	+5.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERC Cerecor	$14.41 -9.5%	$2.60	$1.98 ▼ $4.50	$1.38B	1.44	1.27 million shs	1.58 million shs
CRBP Corbus Pharmaceuticals	$10.38	$9.17	$7.12 ▼ $20.56	$193.81M	2.59	365,355 shs	604,014 shs
HROW Harrow	$40.95	$41.46	$28.54 ▼ $54.85	$1.54B	0.28	554,617 shs	466,460 shs
MNOV MediciNova	$1.39	$1.35	$1.17 ▼ $1.96	$68.42M	0.63	33,471 shs	25,994 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERC Cerecor	0.00%	0.00%	0.00%	0.00%	+45.85%
CRBP Corbus Pharmaceuticals	0.00%	+2.87%	+13.20%	-8.55%	+6.03%
HROW Harrow	0.00%	+2.30%	+6.50%	+24.09%	+4.68%
MNOV MediciNova	0.00%	+6.11%	+5.30%	-0.71%	+5.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERC Cerecor	0.00	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	294.99% Upside
HROW Harrow	2.55	Moderate Buy	$69.43	69.54% Upside
MNOV MediciNova	2.67	Moderate Buy	$8.33	499.52% Upside

Current Analyst Ratings Breakdown

Latest MNOV, CRBP, CERC, and HROW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	HROW Harrow	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$63.00
8/7/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$52.00 ➝ $48.00
8/7/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $35.00
7/21/2026	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$63.00
7/20/2026	HROW Harrow	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	CRBP Corbus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$44.00 ➝ $34.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERC Cerecor	$6.70M	206.49	N/A	N/A	$0.22 per share	65.50
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
HROW Harrow	$275.59M	5.57	$0.86 per share	47.38	$1.41 per share	29.04
MNOV MediciNova	$410K	166.87	N/A	N/A	$0.85 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERC Cerecor	-$63.50M	-$0.57	N/A	N/A	N/A	-1,194.82%	-261.82%	-133.96%	N/A
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	11/11/2026 (Estimated)
HROW Harrow	-$5.14M	-$1.00	N/A	18.78	N/A	-13.51%	-38.00%	-3.37%	11/9/2026 (Estimated)
MNOV MediciNova	-$12M	-$0.21	N/A	N/A	N/A	-1,168.70%	-26.51%	-24.39%	11/12/2026 (Estimated)

Latest MNOV, CRBP, CERC, and HROW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MNOV MediciNova	-$0.0633	-$0.05	+$0.0133	-$0.05	$0.08 million	$0.46 million
8/10/2026	Q2 2026	HROW Harrow	-$0.1788	-$0.46	-$0.2813	-$0.46	$70.35 million	$70.66 million
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERC Cerecor	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERC Cerecor	0.79	2.19	2.18
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
HROW Harrow	19.70	2.24	2.08
MNOV MediciNova	N/A	8.75	8.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERC Cerecor	62.84%
CRBP Corbus Pharmaceuticals	64.64%
HROW Harrow	72.76%
MNOV MediciNova	9.90%

Insider Ownership

Company	Insider Ownership
CERC Cerecor	45.70%
CRBP Corbus Pharmaceuticals	3.50%
HROW Harrow	12.80%
MNOV MediciNova	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERC Cerecor	31	96.01 million	N/A	Not Optionable
CRBP Corbus Pharmaceuticals	40	18.67 million	18.02 million	Optionable
HROW Harrow	180	37.49 million	32.69 million	Optionable
MNOV MediciNova	10	49.22 million	42.33 million	Optionable

MNOV, CRBP, CERC, and HROW Headlines

Recent News About These Companies

MediciNova, Inc. (NASDAQ:MNOV) Given Average Rating of "Moderate Buy" by Brokerages

August 20, 2026 | marketbeat.com

FY2026 EPS Estimates for MediciNova Cut by HC Wainwright

August 20, 2026 | americanbankingnews.com

FY2026 EPS Estimates for MediciNova Lowered by HC Wainwright

August 18, 2026 | marketbeat.com

FY2028 EPS Estimates for MediciNova Reduced by HC Wainwright

August 17, 2026 | americanbankingnews.com

FY2028 EPS Estimates for MediciNova Lowered by HC Wainwright

August 17, 2026 | marketbeat.com

MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results

August 13, 2026 | marketbeat.com

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

August 13, 2026 | zacks.com

MediciNova (MNOV) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts

July 26, 2026 | marketbeat.com

MediciNova Achieves Full Enrollment in NIH-Funded SEANOBI-ALS Study of MN-166 (Ibudilast) for ALS

July 15, 2026 | quiverquant.comQ

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

July 15, 2026 | globenewswire.com

MediciNova CEO Provides Shareholder Update

June 30, 2026 | globenewswire.com

MediciNova Shareholders Reject Proposal to Increase Authorized Stock

June 24, 2026 | tipranks.com

MNOV Share News Today

June 21, 2026 | uk.investing.com

MediciNova (MNOV) Stock Forecast & Price Target

June 11, 2026 | investing.com

MediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026 | finanznachrichten.de

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026 | globenewswire.com

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical ...

May 26, 2026 | caledonianrecord.comC

MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes

May 26, 2026 | quiverquant.comQ

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

May 26, 2026 | globenewswire.com

MediciNova Announces New Insights on Brain Metastasis Vulnerability and Potential Therapeutic Strategies from CNIO Study

April 27, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, CRBP, CERC, and HROW Company Descriptions

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Corbus Pharmaceuticals NASDAQ:CRBP

$10.38 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Harrow NASDAQ:HROW

$40.95 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

MediciNova NASDAQ:MNOV

$1.39 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNOV, CRBP, CERC, and HROW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNOV, CRBP, CERC, and HROW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNOV, CRBP, CERC, and HROW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, CRBP, CERC, and HROW Company Descriptions

Cerecor NASDAQ:CERC

Corbus Pharmaceuticals NASDAQ:CRBP

Harrow NASDAQ:HROW

MediciNova NASDAQ:MNOV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNOV, CRBP, CERC, and HROW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNOV, CRBP, CERC, and HROW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNOV, CRBP, CERC, and HROW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, CRBP, CERC, and HROW Company Descriptions

Cerecor NASDAQ:CERC

Corbus Pharmaceuticals NASDAQ:CRBP

Harrow NASDAQ:HROW

MediciNova NASDAQ:MNOV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools